NICEFIT-ON: A Study Under Routine Clinical Practice in Taiwan to Observe the Long-term Outcome of People With Certain Types of Lung Disease (PF-ILD, SSc-ILD, IPF) Who Start Treatment With Nintedanib

Inclusion Criteria:

This study plans to enroll approximately 500 patients with IPF/SSc-ILD/PF-ILD who newly initiate nintedanib per physicians' discretion within 6 months before participating in the study.

IPF cohort:

• Diagnosed with IPF during the prior 6 months before study enrollment, based on the 2018 ATS/ERS/JRS/ALAT guideline

• Patient ≥ 40 years of age

• Newly initiating nintedanib within 6 months prior to participating in the study

• Providing written informed consent prior to participating in the study

• Having further follow-up possibility with participating physician during the plannedstudy period

• Ability to read and write in local language

SSc-ILD cohort:

• Diagnosed with SSc-ILD during the prior 6 months before study enrollment, based on 2013 ACR/EULAR

• Patient ≥ 20 years of age

• Newly initiating nintedanib OR not receiving nintedanib per physician's discretion (For patients who diagnosed with SSc-ILD but are not treated with nintedanib onphysician's discretion, they will apply the same inclusion criteria, with baselinecharacteristics collected only) within 6 months prior to participating in the study

• Providing written informed consent prior to participating in the study

• Having further follow-up possibility with participating physician during the plannedstudy period

• Ability to read and write in local language

PF-ILD cohort:

• Diagnosed with PF-ILD (PF-ILD patients will be enrolled only after nintedanibacquires the label approval from TFDA) during the prior 6 months before studyenrollment. The definition of PF-ILD diagnosis is as follows:

--Patients who have ILD with a progressive phenotype, but are not diagnosed withIPF, per physician's judgment. The pathophysiology in these patients ischaracterized by self-sustaining fibrosis and a deterioration in lung function overtime, with worsening respiratory symptoms, resistance to immune-modulatorytherapies, and ultimately early mortality.

• Patient ≥ 20 years of age

• Newly initiating nintedanib OR not receiving nintedanib per physician's discretion (For patients who diagnosed with PF-ILD but are not treated with nintedanib onphysician's discretion, they will apply the same inclusion criteria, with baselinecharacteristics collected only) within 6 months prior to participating in the study

• Providing written informed consent prior to participating in the study

• Having further follow-up possibility with participating physician during the plannedstudy period

• Ability to read and write in local language

Exclusion Criteria:

• Lung transplantation expected within the next 6 months.

--Included in ongoing interventional trials